Neuropathic Pain Market

This Persistence Market Research report examines the global neuropathic pain market for the period 2016–2024. The primary objective of the report is to offer updates and information related to market opportunities in the global neuropathic pain market and provide insights into developments impacting global businesses and enterprises.

The global neuropathic pain market is segmented on the basis of drug class, indication, distribution channel, and region. This report covers the global neuropathic pain market performance in terms of revenue contribution from various segments and includes a detailed analysis of key trends, drivers, restraints, and opportunities influencing revenue growth of the global neuropathic pain market. Impact analysis of key growth drivers and restraints based on the weighted average model are included in this report to better equip clients with useful decision-making insights. The global neuropathic pain market report begins with an overview of the market and key definitions. The subsequent sections evaluate the present scenario and future growth prospects of the global neuropathic pain market on the basis of drug class, indication, distribution channel, and region and provide a comprehensive market forecast for the next eight years. 

The report provides a market outlook for 2016–2024 and sets the forecast within the context of the global neuropathic pain market. The study further analyzes the extent to which drivers are influencing the market across the key assessed regions of North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

In the final section of the report, a competitive market landscape has been included to provide report audiences with a dashboard view of key players operating in the global neuropathic pain market, along with an analysis of company-specific long-term and short-term strategies, key offerings, and recent developments in the global neuropathic pain market. Top market companies featured in the report include Pfizer Inc., Johnson & Johnson Services Inc., Sanofi S.A., Eli Lily and Company, GlaxoSmithKline PLC, Biogen Idec Inc., Bristol-Myers Squibb and Company, Baxter Healthcare Corporation, and Depomed Inc. Persistence Market Research also provides key strategic recommendations for both existing and new players in the global neuropathic pain market to emerge sustainably profitable.

Research methodology

To ascertain the global neuropathic pain market revenue, the report considers regional revenue contribution and contribution of key players operating in the market. The forecast presented in the report assesses the total revenue generated by value across the global neuropathic pain market and in order to provide an accurate forecast, the report begins by sizing the current market, which forms the basis of how the global neuropathic pain market is anticipated to perform in future. Given the ever-fluctuating nature of the global economy, the report not only conducts forecasts in terms of CAGR, but also analyzes the market based on key parameters such as year-on-year (Y-o-Y) growth to understand market predictability and to identify the right opportunities across the global neuropathic pain market. The different market segments and sub-segments have also been analyzed in terms of Basis Point Share (BPS) to understand individual segments’ relative contribution to market growth. This detailed level of information is important for identifying various trends impacting the global neuropathic pain market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is overlooked while forecasting the market. Absolute dollar opportunity is critical for evaluating the scope of opportunity that a provider can look to achieve, as well as to identify potential resources in the global neuropathic pain market. The overall absolute dollar opportunity along with the segmental split is mentioned in the report. Further, to understand key market segments in terms of growth and performance in the global neuropathic pain market, Persistence Market Research has developed a market attractiveness index to help providers identify real market opportunities across the global neuropathic pain market.

The global neuropathic pain market, estimated to be worth US$ 5200 Mn in 2015, is expected to increase at a CAGR of 5.6% through 2024. North America is the largest market accounting for US$ 1,862.2 Mn in 2015, and is expected to grow at a CAGR of 5.8%.

Factors and trends impacting the market

Diabetes is the most common indication for neuropathic pain followed by cancer. An increasing geriatric population across the globe is expected to drive market demand, as the prevalence of painful diabetic neuropathy is 16% in the global elderly population suffering from diabetes. Increasing prevalence of diabetes and cancer, approval of novel treatment options for neuropathic pain, rise in number of pain management centers, and an increasing demand for treatment of neuropathic pain are major factors driving growth of the global neuropathic pain market. Other trends driving market growth are awareness among patients for treatment of neuropathic pain, increase in the demand for generic drugs, and rapid launches of products for treatment of neuropathic pain. Strong healthcare infrastructure and well-established reimbursements are further driving the growth of the global neuropathic pain market.

Pharmaceutical companies are focusing on development of improved drugs to fulfil unmet needs of patients suffering from neuropathic pain. However, severe side effects of opioids and steroids and rising costs of branded drugs are some of the factors likely to restrain the growth of the global neuropathic pain market over the forecast period.

Market segmentation by Drug Class

Based on drug class, the market has been segmented into Tricyclic Antidepressant, Anticonvulsants, Local Anaesthesia, Opioids, Steroids, and Others. Among these, the Anticonvulsants drug class segment is expected to exhibit the highest growth over the forecast period. Anticonvulsants are the most popular drug class for treatment of neuropathic pain. This segment is anticipated to register a CAGR of 5.8 % over the forecast period. The Tricyclic Antidepressant segment is projected to be the fastest growing segment in the global neuropathic pain market over the forecast period.

Market segmentation by Indication

Based on indication, the market has been segmented into Diabetic Neuropathy, Chemotherapy Induced Peripheral Neuropathy, and Others. The Diabetic Neuropathy segment accounts for the highest revenue share in the market followed by the Chemotherapy Induced Peripheral Neuropathy segment. The Diabetic Neuropathy segment is expected to account for the highest value share of 46.7% of the global neuropathic pain market by the end of 2016. The Chemotherapy Induced Peripheral Neuropathy segment is likely to create incremental opportunity of US$ 1,301.3 Mn between 2016 and 2024.

Market segmentation by Distribution Channel

Based on distribution channel, the market has been segmented into Retail Pharmacies, Drug Stores, and Online Pharmacies. The Retail Pharmacies segment accounts for the highest revenue share in the global neuropathic pain market followed by the Drug Stores segment. Retail pharmacies are preferred by patients more than online pharmacies. The Retail Pharmacies segment is expected to be the most lucrative segment in the global neuropathic pain market, recording a market attractiveness index of 1.5.

Key regions

The global neuropathic pain market is segmented into the key regions of North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. In terms of value, North America is the largest market and is expected to increase at over 5.8% CAGR during the forecast period. The Asia Pacific neuropathic pain market is anticipated to grow by 6.2% due to increasing prevalence of diabetes in Asia Pacific countries such as China and India.

Top market companies

Some of the key players operating in the global neuropathic pain market are Depomed Inc., Pfizer Inc., Johnson & Johnson Services Inc., Bristol-Myers Squibb and Company, Eli Lily and Company, GlaxoSmithKline PLC, Sanofi S.A., Biogen Idec Inc., and Baxter Healthcare Corporation.

Company Profiles 

• Pfizer, Inc.
• Johnson & Johnson Services, Inc.
• Sanofi S.A.
• Eli Lily and Company
• GlaxoSmithKline PLC
• Biogen Idec.
• Bristol-Myers Squibb
• Baxter Healthcare Corporation
• Depomed Inc.
• Others.